Related Experiment Videos
The renoprotective effect of combined antihypertensive drugs
1Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy.
Insights
Achieving a blood pressure target of 125/75 mmHg may slow chronic renal failure (CRF) progression. Certain antihypertensive drugs offer renoprotective benefits beyond blood pressure reduction, especially in combination therapies for CRF patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- A blood pressure (BP) target of 125/75 mmHg is recommended to reduce chronic renal failure (CRF) progression and cardiovascular mortality.
- Specific antihypertensive agents may offer renoprotective effects by targeting CRF pathogenetic mechanisms.
- The superiority of these agents over others at achieving low BP for renoprotection remains unclear.
Purpose of the Study:
- To investigate the renoprotective effects of specific antihypertensive agents beyond BP reduction.
- To explore the potential for additive or synergistic renoprotective effects of combination therapies in CRF patients.
Main Methods:
- Review of existing literature on antihypertensive agents and their effects on CRF progression.
- Analysis of pathogenetic mechanisms of renal damage targeted by ACE inhibitors, calcium channel blockers, and angiotensin receptor antagonists.
- Evaluation of evidence for BP-independent renoprotective effects and combination therapy benefits.
Main Results:
- Certain antihypertensive drugs (e.g., ACE inhibitors, ARBs) may slow CRF progression through mechanisms independent of BP reduction.
- The comparative efficacy of these drugs versus other agents at achieving renoprotection at low BP levels requires further investigation.
- Combination treatments hold promise for additive or synergistic renoprotective effects in CRF management.
Conclusions:
- Antihypertensive agents targeting specific pathways may offer renoprotection beyond BP control in CRF.
- Further research is needed to clarify the role of these agents and combination therapies in optimizing renoprotection.
- Multidrug regimens are essential for adequate BP management in most CRF patients, presenting opportunities for enhanced renoprotection.
Abstract:
In recent years, a target blood pressure (BP) of at least 125/75 mmHg has been sought in order to reduce the rate of progression of chronic renal failure (CRF) and cardiovascular mortality. Some antihypertensive agents, such as ACE inhibitors, calcium channel blockers and angiotensin receptor antagonists (and perhaps endothelin converting enzyme inhibitors and endothelin antagonists), may also reduce CRF progression because they block some of the pathogenetic mechanisms involved in renal damage. Although this effect seems to be partially independent of BP reduction, it is still not clear whether these drugs are really superior to other antihypertensive agents when low BP is achieved. However, the possibility that combination treatments with some of these drugs may confer additive or even synergistic renoprotective effects other than BP control is not only fascinating, but also important because multidrug antihypertensive regimens are required anyway to manage BP adequately in the majority of patients with CRF.